Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 2,549 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pharmacokinetic study Clear all
Completed Phase 3 Interventional Results available

Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema

NCT00490815
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy

NCT02221869
View directory record Official record
Conditions
Narcolepsy With Cataplexy
Interventions
Xyrem
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
7 Years to 17 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
17
States / cities
Long Beach, California • Orange, California • Redwood City, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 17, 2026, 5:16 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and PK Study of BICX104 With or Without Bupropion Compared to Vivitrol

NCT07269873
View directory record Official record
Conditions
Healthy Adult Male and Female Volunteers
Interventions
BICX104 naltrexone implantable pellet, Bupropion 150 mg XL, Naltrexone (depot)
Drug
Lead sponsor
BioCorRx Pharmaceuticals Inc
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies

NCT01781429
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BVD-523
Drug
Lead sponsor
BioMed Valley Discoveries, Inc
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
9
States / cities
Los Angeles, California • New Haven, Connecticut • Sarasota, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 1 Interventional

Tipifarnib in Treating Young Patients With Refractory Leukemia

NCT00022451
View directory record Official record
Conditions
Leukemia
Interventions
tipifarnib
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
56
States / cities
Little Rock, Arkansas • Duarte, California • La Jolla, California + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.

NCT01437384
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura (ITP)
Interventions
E5501
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 1 Interventional Results available

PK Study of Dapagliflozin in Pediatric Subjects With T2DM

NCT01525238
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Not applicable Interventional

A Multi-Center, Open-Label, Ascending, Multiple Oral Dose, Safety, Tolerance and Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Patients With Acquired Immune Deficiency Syndrome (AIDS) or AIDS-Related Complex (ARC)

NCT00002254
View directory record Official record
Conditions
HIV Infections
Interventions
Alovudine
Drug
Lead sponsor
Lederle Laboratories
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacokinetic and Pharmacodynamic Study of Cyclofem

NCT01699022
View directory record Official record
Conditions
Contraception
Interventions
Injection Cyclofem
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine and Compare Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam in Healthy Subjects

NCT03303924
View directory record Official record
Conditions
Healthy
Interventions
ETX2514 and sulbactam
Drug
Lead sponsor
Entasis Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 17, 2026, 5:16 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

NCT03690869
View directory record Official record
Conditions
Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, High Grade Glioma
Interventions
cemiplimab (monotherapy), cemiplimab (maintenance), Conventional or hypofractionated, Re-irradiation
Drug · Radiation
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
Up to 25 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 17, 2026, 5:16 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas

NCT03262116
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Humalog, Novolog, BC222 insulin lispro, Bionic Pancreas
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Evaluation of Intranasal and Intramuscular Naloxone in Healthy Volunteers

NCT02572089
View directory record Official record
Conditions
Drug Overdose, Opioid-Related Disorders
Interventions
Naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Desogestrel-containing COCP Pharmacokinetic Validation Study

NCT05002738
View directory record Official record
Conditions
Contraception
Interventions
Desogestrel and Ethinyl Estradiol Tablets
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy

NCT01643408
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions
asparaginase Erwinia chrysanthemi
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Los Angeles, California • Orange County, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety and Pharmacokinetic Study of Proellex®

NCT00619385
View directory record Official record
Conditions
Healthy
Interventions
Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 34 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2014 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment

NCT02245243
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Delafloxacin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

NCT02535091
View directory record Official record
Conditions
Partial Epilepsy
Interventions
YKP3089
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
39
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Metformin and Furosemide Drug-Drug Interaction Study

NCT02028689
View directory record Official record
Conditions
Healthy
Interventions
Lesinurad 400 mg, Metformin 850 mg, Furosemide 40 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of AG-348 in Healthy Volunteers

NCT02149966
View directory record Official record
Conditions
Healthy Volunteer
Interventions
AG-348, Placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2014 · Synced Oct 17, 2026, 5:16 AM EDT
Terminated Phase 1 Interventional

Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

NCT02134067
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
TAS-119, Paclitaxel
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
Aurora, Colorado • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers

NCT01572012
View directory record Official record
Conditions
Healthy
Interventions
Ondansetron, Ondansetron + Hylenex, Zofran ODT, Ondansetron solution
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
19 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetic Study of S-Equol in Healthy Volunteers

NCT00787007
View directory record Official record
Conditions
Healthy
Interventions
S-equol, Placebo
Drug
Lead sponsor
Ausio Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 20, 2012 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT03118765
View directory record Official record
Conditions
Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Interventions
GSP304 (tiotropium bromide) Inhalation Solution, GSP304 Placebo Inhalation Solution, Spiriva® Respimat® inhalation spray
Drug
Lead sponsor
Glenmark Specialty S.A.
Industry
Eligibility
40 Years to 85 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
25
States / cities
Andalusia, Alabama • Phoenix, Arizona • Tempe, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 17, 2026, 5:16 AM EDT